NCT03745287: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
- State
- Completed
- Phase
- Phase 2 and Phase 3
- People
- 63 taking part
- Started
- 27 Nov 2018
- Primary completion
- 7 Jul 2025
- Arms
- Exa-cel
- Results
- Posted on the registry
- Papers
- doi:10.1002/pbc.30274, doi:10.1002/pbc.30319, doi:10.1016/bs.pmbts.2021.01.025, doi:10.1016/j.jcyt.2022.08.003, doi:10.1016/j.jtct.2024.06.006, doi:10.1038/s41434-020-00192-z, doi:10.1056/nejmoa2031054, doi:10.1056/nejmoa2309676, doi:10.1182/bloodadvances.2025016701
- 19 Nov 2018: Trial registered
- 27 Nov 2018: Trial started
- 7 Jul 2025: Trial completed
- 16 Sep 2026: Trial results posted